Pembrolizumab
G12D Mutated KRAS
Verastem, Inc.monoclonal_antibodyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the G12D Mutated KRAS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab Verastem, Inc. | Phase 2 | B |
vs-7375 Verastem, Inc. | Phase 2 | B |
Capecitabine Verastem, Inc. | Phase 1/2 | CC |
Carboplatin Verastem, Inc. | Phase 1/2 | CC |
Same molecule, other indications
Pembrolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →